非布司他对访视间血压变异性的影响:随机PRIZE研究的启示
本文为PRIZE随机试验的子分析,纳入472例高尿酸血症合并颈动脉斑块患者,随机分入非布司他组或对照组,随访24个月。非布司他组调整后平均收缩压、收缩压变异系数及脉率标准差均低于对照组,提示黄嘌呤氧化酶抑制与非布司他降低访视间血压变异性相关。
要点
- 非布司他组调整后平均收缩压128.4 mmHg vs 对照组130.7 mmHg(p=0.04)。
- 非布司他组收缩压变异系数7.4 vs 对照组8.2(p=0.04)。
- 非布司他组脉率调整后标准差5.95 vs 对照组7.33(p=0.04)。
核心结论
- 在高尿酸血症合并颈动脉斑块患者中,使用非布司他抑制黄嘌呤氧化酶与访视间血压变异性降低及脉率变异性降低相关。
研究设计与样本
- 本研究为PRIZE随机试验的子分析,该随机试验旨在评估非布司他对颈动脉内膜中层厚度进展的潜在影响。
- 高尿酸血症合并颈动脉斑块患者被随机分配至非布司他组或对照组,在24个月期间诊室血压和脉率测量≥3次。
- 血压和脉率变异性采用标准差(SD)和变异系数(CV)评估,非布司他的效应经年龄、性别及基线血压或脉率调整,以95%CI表示。
主要发现
- 本子分析共纳入472例患者。
- 在24个月随访期间,非布司他组调整后平均收缩压为128.4(126.8-130.0)mmHg,对照组为130.7(129.1-132.2)mmHg,p=0.04。
- 非布司他组收缩压变异系数为7.4(6.7-8.0),对照组为8.2(7.6-8.8),p=0.04。
- 非布司他组脉率调整后标准差为5.95(4.93-6.97),对照组为7.33(6.32-8.33),p=0.04。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Although uric acid lowering therapies, including xanthine oxidase (XO) inhibition, may reduce the absolute level of blood pressure (BP), the effect of XO inhibition on BP variability is largely unknown. The aim of the present analysis was to evaluate the impact of febuxostat, an XO inhibitor, on BP variability in a randomised trial setting. METHODS: This was a subanalysis of the PRIZE Study, a randomised trial to evaluate the potential effect of febuxostat on carotid intima-media thickness progression. Patients with hyperuricemia and carotid plaques were randomly assigned to the febuxostat or control group. During a 24-month period, office BP and pulse rate (PR) were measured ≥3 times. BP and PR variabilities were assessed with SD and coefficient of variation (CV). The effect of febuxostat on BP and PR variabilities was adjusted with age, sex and baseline BP or PR, expressed with 95% CIs. RESULTS: A total of 472 patients were included into the present subanalysis. During the 24-month follow-up period, the febuxostat group had a significantly lower adjusted mean systolic BP (128.4 (126.8-130.0) vs 130.7 (129.1-132.2) mm Hg, p=0.04) and CV of systolic BP (7.4 (6.7-8.0) vs 8.2 (7.6-8.8), p=0.04) than the control group. Adjusted SD of PR was also lower in the febuxostat group than their counterpart (5.95 (4.93-6.97) vs 7.33 (6.32-8.33), p=0.04). CONCLUSION: XO inhibition with febuxostat was associated with reduced visit-to-visit BP variability as well as reduced PR variability in patients with hyperuricemia and carotid plaques. TRIAL REGISTRATION NUMBERS: University Hospital Medical Information Network Clinical Trial Registry (UMIN000012911 and UMIN000041322).
引用
- Saito Y, Tanaka A, Koide Y, et al. Impact of febuxostat on visit-to-visit blood pressure variability: insights from the randomised PRIZE Study. RMD Open. 2022. PMID: 36109083. doi:10.1136/rmdopen-2022-002505
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。